Zacks Research Issues Negative Outlook for Zoetis Earnings

Zoetis Inc. (NYSE:ZTS) – Analysts at Zacks Research decreased their Q2 2025 earnings estimates for shares of Zoetis in a report issued on Monday, November 25th. Zacks Research analyst E. Bagri now expects that the company will earn $1.66 per share for the quarter, down from their previous estimate of $1.68. The consensus estimate for Zoetis’ current full-year earnings is $5.90 per share. Zacks Research also issued estimates for Zoetis’ Q3 2025 earnings at $1.65 EPS, FY2025 earnings at $6.37 EPS, Q2 2026 earnings at $1.76 EPS and FY2026 earnings at $6.91 EPS.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The firm had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.29 billion. During the same quarter in the prior year, the firm earned $1.36 EPS. Zoetis’s revenue for the quarter was up 11.6% on a year-over-year basis.

A number of other equities analysts have also recently weighed in on the stock. Stifel Nicolaus upped their price target on shares of Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research note on Wednesday, September 18th. Piper Sandler upped their price target on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. Argus raised shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. BTIG Research upped their price target on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Finally, JPMorgan Chase & Co. upped their price target on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Ten equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Zoetis presently has an average rating of “Buy” and an average price target of $221.44.

Zoetis Stock Up 0.6 %

Shares of Zoetis stock opened at $176.74 on Thursday. The company has a market cap of $79.74 billion, a P/E ratio of 33.22, a PEG ratio of 2.70 and a beta of 0.90. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. Zoetis has a one year low of $144.80 and a one year high of $201.92. The firm has a fifty day moving average of $184.18 and a two-hundred day moving average of $180.78.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be issued a $0.432 dividend. The ex-dividend date of this dividend is Thursday, October 31st. This represents a $1.73 annualized dividend and a yield of 0.98%. Zoetis’s payout ratio is 32.52%.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of ZTS. Darwin Wealth Management LLC purchased a new stake in shares of Zoetis during the third quarter valued at approximately $31,000. First Personal Financial Services purchased a new stake in shares of Zoetis during the third quarter valued at approximately $33,000. Capital Performance Advisors LLP purchased a new stake in shares of Zoetis during the third quarter valued at approximately $33,000. Dunhill Financial LLC raised its stake in shares of Zoetis by 80.6% during the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after purchasing an additional 75 shares during the period. Finally, Quarry LP raised its stake in shares of Zoetis by 273.2% during the second quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after purchasing an additional 153 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.